• Non ci sono risultati.

La Rete oncologica ligure

N/A
N/A
Protected

Academic year: 2022

Condividi "La Rete oncologica ligure"

Copied!
21
0
0

Testo completo

(1)

Il contributo della ROLi nella ricerca oncologica

P Pronzato

Milano, 19.11.2016

AIOM LOMBARDIA, LIGURIA, PIEMONTE E VALLE D’AOSTA

(2)

ROLi e Ricerca

Un Ruolo per lo Sviluppo di Nuovi

Trattamenti?

(3)
(4)

Slide 6

Presented By Martine Piccart-Gebhart at 2015 ASCO Annual Meeting

(5)

Slide 16

Presented By Martine Piccart-Gebhart at 2015 ASCO Annual Meeting

(6)

Vemurafenib Basket Trial: BRAF V600 Mutant Nonmelanoma Cancers

Presented By Lillian Siu at 2016 ASCO Annual Meeting

(7)

Limits and Solutions

M Arnedos, Nat Rev Clin Oncol 2015

(8)

Un ruolo per la Rete

• Det. AIFA 80/15 & Regolamento UE 536/2014

• Costi della Ricerca Clinica

• Solo Reclutamento e Follow-Up?

• Rete di Centri di Sperimentazione Clinica

– CE Regionale

Core Facilities di Rete

(9)

Guida per le reti: differenti modelli

Fig. 4 Comprehensive Cancer Care Network (CCCN)

Intesa 30/10/14 DM 70 /20015 CANCON BU - RNTR

(10)

ROLi e Ricerca

Un Ruolo per una nuova Ricerca?

(11)
(12)

Simultaneous Care

Comfort Care

R Parih, NEJM 2014; CD Blinderman, NEJM 2016

(13)

Slide 53

Presented By Ralph Wong at 2016 ASCO Annual Meeting

(14)
(15)

TERAPIA INTENSIVA

DEA

CURE INTERMEDIE

D D

D

AREA MEDICA AREA CHIRURGICA MAT-INF

D D

D

TERRITORIO

(16)

AREA MATERNO INFANTILE

TERAPIA INTENSIVA

DH – DAY SURGERY - DSA AMBULATORI

DEA

CURE INTERMEDIE

AREA MEDICA AREA CHIRURGICA

TERRITORIO

PIASTRA HIGH TECH

(17)

Cancer

Obesity

Hyperglycemia

Hyperinsulinemia

Obesità, Insulinoresistenza e Cancro:

Fisiopatologia

Diabetes / Diabetes Drugs

Inflammation

Diet

Physical Activity

Adipokines

(18)

Even Common Cancers are becoming Rare

(19)
(20)

Tolerating Uncertainty. The Next Medical Revolution

A Simpkin, NEJM 2016

(21)

Un ruolo per la Rete

Studi Osservazionali

Età

ComorbiditàGenere

Traiettorie

Sviluppo di Indicatori

Tumori Rari

Coping

HTA

End of Life

Riferimenti

Documenti correlati

Presented By Hedy Kindler at 2019 ASCO Annual Meeting... Come spiegare PFS

Presented By Robert Uzzo at 2019 ASCO Annual Meeting... CARMENA: Prospective, multicenter, open-label, randomized, phase 3

Presented By Jeffrey Weber at 2018 ASCO Annual Meeting... Subgroup Analysis of RFS: Disease Stage III

Presented By Heather Cheng at 2018 ASCO Annual Meeting.. Germline pathogenic alterations may have both familial and

Presented By Michael Morse at 2018 ASCO Annual Meeting... Response rate to anti-PD1 and mutational

Presented By Keith Kerr at 2015 ASCO Annual Meeting.. Biomarker not predictive in Squamous (017) <br />but predictive in

Precis Oncol 2018 Presented by Christine Lovly at 2018 ASCO Annual Meeting.. E non finisce qui: Ensartinib, Entrectinib, TPX-0005

Immune effects of Chemotherapy, Radiation Therapy and Targeted Therapies.. Presented By Sandra Demaria at 2017 ASCO